RLMD

Relmada TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$5.50

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$2.95

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$1.65

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-25

AI commentary

Cautious, milestone-driven monitoring view. The August company release supports the development timetable and cash position, while the September 8-K confirms a leadership departure. [#SEC-8K-2026-08-06] [#8-K-2026-09-08] The $3.27 anchor is dated October 23; a verified recent price reaction, analyst revisions, options data, short interest, employee ratings, and sufficient social coverage were not supplied. Zero-valued sentiment fields denote unavailable measurements, not neutral observations. Low coverage and a negative deterministic prior limit conviction.

RankAlpha Sentiment Codex - 2026-10-25

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventNDV-01 IND submissionHigh impact

Relmada targets a year-end 2026 IND filing for NDV-01, with GMP manufacturing and CMC work still the immediate execution gate. A filing could reduce uncertainty; another delay would weaken the near-term thesis. Probability and price impact are analyst estimates, not company guidance. [#SEC-8K-2026-08-06]

2026-12-31eventSepranolone IND submissionHigh impact

Relmada targets a year-end 2026 sepranolone IND filing for a planned Phase 2 Prader-Willi syndrome study. The company identified completion of the pre-filled syringe delivery system as the remaining formulation step. Estimates are conditional on execution. [#SEC-8K-2026-08-06]

2027-03-31catalystNDV-01 Phase 3 RESCUE initiationHigh impact

Relmada plans to initiate RESCUE after IND clearance and says trial sites are engaged. March 2027 is a monitoring estimate, not a company-promised start date; manufacturing or regulatory delays could push enrollment later. [#SEC-8K-2026-08-06]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-25 • Updated nightlySource: Internal modelMethodology